Heart Beat: Follow-up: Limit Natrecor to hospital use, say experts
Heart Beat
Follow-up: Limit Natrecor to hospital use, say experts
An independent panel of experts took a hard look at the safety of Natrecor (nesiritide), a controversial heart failure drug, and how it is used during the summer of 2005.
The panel, headed by Dr. Eugene Braunwald, a preeminent heart failure specialist and member of the Harvard Heart Letter editorial board, made these recommendations:
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.
Sign Me UpAlready a member? Login ».
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.